Chronic News and Research

RSS

Emergent commences TRU-016 Phase 1b/2 combination trial in relapsed indolent NHL

Emergent BioSolutions Inc. today announced the initiation of a Phase 1b/2 study (16011) of TRU-016 in combination with rituximab and bendamustine for patients with relapsed indolent non-Hodgkin's B-cell lymphomas, including follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma.

17 Aug 2011

OrbusNeich's Genous Stent safe, effective for patients at high risk of restenosis

OrbusNeich today announced that the that the company's Genous Stent showed no significant difference in the rate of target vessel failure (TVF) at two years compared to the Taxus Liberte™ paclitaxel-eluting stent in patients with de novo coronary artery lesions carrying a high risk for restenosis.

17 Aug 2011

New tool can identify patients at high risk of venous thromboembolism

A new risk prediction tool can identify patients at high risk of serious blood clots (known as venous thromboembolism) who might need preventative treatment, says a study published on bmj.com today.

17 Aug 2011

Pegloticase can improve clinical outcomes of patients with chronic gout

Injections of pegloticase, a modified porcine enzyme, can produce significant and sustained clinical improvements in 2 out of 5 patients with chronic gout that is resistant to conventional therapies, researchers report in the August 17, 2011, issue of JAMA.

17 Aug 2011

Seattle Children's receives Gates Foundation grant to complete development of Sea-PAP

Seattle Children's Research Institute today announced the receipt of a two-year, $2.3 million grant from the Bill & Melinda Gates Foundation to complete prototype development of its new respiratory support device, called Seattle Children's Positive Airway Pressure.

17 Aug 2011

New research: Blood stem cells can be involved in pathogenesis of CLL

New research suggests that blood stem cells can be involved in the generation of leukemia, even when the leukemia is caused by the abnormal proliferation of mature cells. The study, published by Cell Press in the August 16th issue of the journal Cancer Cell, may guide future strategies aimed at identifying therapeutic targets for chronic lymphocytic leukemia.

17 Aug 2011

FDA clears Inhibikase IkT-001 Phase II trial to treat JCV infection in multiple sclerosis patients

Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).

17 Aug 2011

Assured Pharmacy second quarter net sales increase 5.3% to $4,169,807

Assured Pharmacy, a leading specialty pharmacy group providing prescription medications to sufferers of chronic pain, announced net sales of $4,169,807 for the quarter ended June 30, 2011, an increase of $211,229 or 5.3%, from $3,958,578 for the second quarter of 2010.

16 Aug 2011

Scientists demonstrate how Modified Citrus Pectin enhances immune function

Groundbreaking research demonstrates the ability of a specific form of Modified Citrus Pectin (MCP) to greatly enhance immune function.

16 Aug 2011

Geisinger researchers develop new PTSD prediction tool

A new post-traumatic stress disorder (PTSD) prediction tool, developed by Geisinger Health System researchers, is simple to administer and appears to outperform other screening methods, according to new findings published electronically in the August issue of the journal General Hospital Psychiatry.

16 Aug 2011

Study confirms that vitamin D deficiency increases aggressiveness of colon cancer

A study conducted by VHIO researchers confirms that a lack of vitamin D increases the aggressiveness of colon cancer.

16 Aug 2011

Parents view children's nut allergies as 'frivolous and self-indulgent fad'

Parents of nut-allergy sufferers face hostility and scepticism in trying to find safe environments for their children, a new study has found.

16 Aug 2011

Caffeine might help prevent skin cancer

A new Rutgers study strengthens the theory that caffeine guards against certain skin cancers at the molecular level by inhibiting a protein enzyme in the skin, known as ATR. Scientists believe that based on what they have learned studying mice, caffeine applied directly to the skin might help prevent damaging UV light from causing skin cancer.

16 Aug 2011

Pain care management needs to be improved: CMAJ

Pain care management needs to be improved, with health care professionals committing to improve care as well as a retooling of the health care system to help people who are suffering, states an editorial in CMAJ.

16 Aug 2011

Research: Decoding infidelity may increase risk of type 2 diabetes

Type 2 diabetes is an extremely common chronic condition characterized by high levels of sugar in the blood as a result of either insufficient production of the hormone insulin or an inability of cells to respond to insulin.

16 Aug 2011

An hour of TV a day shortens lifespan by 22 minutes: Study

Researchers have found that watching too much TV is as dangerous as smoking or being overweight, and that the “ubiquitous sedentary behaviour” should be seen as a “public health problem”.

16 Aug 2011

Toclizumab for juvenile rheumatoid arthritis

The arthritis drug Toclizumab could be a boon for hundreds of children suffering from severe arthritis. It has been re-launched in children after being already licensed for the treatment of adults. At least two thirds of children taking tocizilumab have been able to return to a normal life, after many were bedridden or forced into wheelchairs by the disease, the clinical studies reveal.

16 Aug 2011

Thorne acquires global rights to Q-Cell, an advanced formulation Coenzyme Q10

Thorne Research, Inc., a leader in developing and manufacturing pure, high quality nutritional supplements marketed through licensed healthcare practitioners, has acquired exclusive global rights to market Q-Cell, an advanced formulation Coenzyme Q10 (CoQ10) supplement formerly marketed under the brand name Q-Best.

12 Aug 2011

Galectin second quarter net loss increases to $3.9 million

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the second quarter and first six months, ended June 30, 2011.

12 Aug 2011

Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis

For nearly 60 years, Pyrazinamide (PZA) has been used in conjunction with other medications to treat tuberculosis (TB), but scientists did not fully understand how the drug killed TB bacteria. PZA plays a unique role in shortening the duration of current TB therapy to six months and is used frequently to treat multi-drug resistant TB.

12 Aug 2011